IN THE HIGH COURT OF NEW ZEALAND WELLINGTON REGISTRY
I TE KŌTI MATUA O AOTEAROA TE WHANGANUI-A-TARA ROHE
CIV-2018-485-741
[2019] NZHC 1520
BETWEEN PHARMAZEN LIMITED
Appellant
AND
ANAGENIX IP LIMITED
Respondent
Hearing: 25 March 2019 Appearances:
J V Ormsby and T M Ritchie for the Appellant S Wheeldon for the Respondent
Judgment:
1 July 2019
JUDGMENT OF CULL J
TABLE OF CONTENTS
Background 7
The Commissioner’s decision 9
Approach to appeal 12
Preliminary issue of evidence 18
Legal framework 22
Issues 27
Issue One: whether the goods are similar 28
Issue Two: whether the trade marks are similar 40
Visual comparison 43
Aural Comparison 49
Conceptual/descriptive comparison 54
Discussion 58
Issue Three: whether the trade mark would be likely to deceive or confuse 64
Result 80
[1] Pharmazen Limited’s (Pharmazen) application to register its trademark, ActiPhen, was declined by the Assistant Commissioner of Trade Marks (the Commissioner).1 Pharmazen appeals the Commissioner’s decision (the Decision).
1 Pharmazen Limited v Anagenix IP Limited [2018] NZIPOTM 27.
PHARMAZEN LIMITED v ANAGENIX IP LIMITED [2019] NZHC 1520 [1 July 2019]
[2] The Commissioner found that the ActiPhen trademark is similar to Anagenix IP Limited’s (Anagenix) mark, ACTAZIN,2 is in respect of similar goods,3 and that it is likely a significant number of persons in the relevant market would be deceived or confused by Pharmazen’s use of the mark under s 25(1)(b) of the Trade Marks Act 2002 (the Act).4
[3] Although Anagenix was successful under s 25(1)(b) of the Act, the Commissioner went on to find Anagenix failed in its other grounds of opposition under s 17(1) of the Act. Section 17(1)(a) requires that the use of the applied-for trade mark must not be likely to deceive or confuse, and s 17(1)(b) requires that the use of the applied-for trade mark must not be contrary to the Fair Trading Act 1986 or other New Zealand law for being misleading or deceptive.
[4] Pharmazen appeals the Decision under s 170 of the Act. Pharmazen submits that the Commissioner’s Decision relating to s 25(1)(b) is wrong and inconsistent with other findings made by the Commissioner: the same conclusions which led Anagenix to fail in respect of s 17(1)(a) must necessarily mean that Anagenix fails under s 25(1)(b).
[5]Accordingly, Pharmazen submits:
(a)the Commissioner erred in fact and law in finding that the goods are similar;
(b)the Commissioner erred in fact and law in finding that the trade marks are similar; and
(c)the Commissioner erred in fact and law in finding that a significant number of persons in New Zealand would be deceived or confused by Pharmazen’s use of the ActiPhen mark.
2 At [65].
3 At [53].
4 At [69].
[6] Anagenix submits the Commissioner made no error in fact or in law: the goods are similar and the marks are similar, such that Pharmazen’s use of the ActiPhen mark would be likely to deceive or confuse a significant number of people.
Background
[7] On 4 May 2016, Pharmazen lodged an application to register the “ActiPhen” trade…
Keep reading for free
Create a free CaseChat account to read Pharmazen Limited v Anagenix IP Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2019] NZHC 1520
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi